Markets open

Alnylam Pharmaceuticals, Inc.

ALNY · Nasdaq

Analyst Consensus

Buy

26 analysts

$228

Current

—

Low

$375

Average

—

High

Average target implies +64.52% versus the current price.

The ratings synthesis for ALNY has not been generated yet.

Rating Actions

No individual rating actions have been captured for ALNYyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BMO CAPITAL MKT

CANACCORD GENUI

CANTOR FITZGERA

CHARDAN CAPITAL

CITIGROUP

EVERCORE ISI

GOLDMAN SACHS

GUGGENHEIM SEC.

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: ALNY
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health.